Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Humoral immunity to tetanus, diphtheria and polio in adults after treatment for hematological malignancies.

Einarsdottir S, Ljungman P, Kaijser B, Nicklasson M, Horal P, Norder H, Bergström T, Brune M.

Vaccine. 2019 Nov 28. pii: S0264-410X(19)31559-2. doi: 10.1016/j.vaccine.2019.11.034. [Epub ahead of print]

PMID:
31787417
2.

Combined Testing of p16 Tumour-suppressor Protein and Human Papillomavirus in Patients With Oral Leukoplakia and Oral Squamous Cell Carcinoma.

Sundberg J, Korytowska M, Burgos PM, Blomgren J, Blomstrand L, DE Lara S, Sand L, Hirsch JM, Holmberg E, Giglio D, Öhman J, Kovács A, Horal P, Lindh M, Kjeller G, Hasséus B.

Anticancer Res. 2019 Mar;39(3):1293-1300. doi: 10.21873/anticanres.13241.

PMID:
30842161
3.

Type-dependent E6/E7 mRNA expression of single and multiple high-risk human papillomavirus infections in cervical neoplasia.

Andersson E, Kärrberg C, Rådberg T, Blomqvist L, Zetterqvist BM, Ryd W, Lindh M, Horal P.

J Clin Virol. 2012 May;54(1):61-5. doi: 10.1016/j.jcv.2012.01.012. Epub 2012 Feb 10.

PMID:
22326759
4.

Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.

Andersson E, Kärrberg C, Rådberg T, Blomqvist L, Zetterqvist BM, Ryd W, Lindh M, Horal P.

J Clin Microbiol. 2011 Nov;49(11):3794-9. doi: 10.1128/JCM.00549-11. Epub 2011 Sep 21.

5.

[Correct but partly misleading about a laboratory test].

Horal P, Strannegård O.

Lakartidningen. 2009 Feb 4-10;106(6):378; author reply 378. Swedish. No abstract available.

PMID:
19297822
6.

Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Abdurahman S, Végvári A, Youssefi M, Levi M, Höglund S, Andersson E, Horal P, Svennerholm B, Balzarini J, Vahlne A.

Antimicrob Agents Chemother. 2008 Oct;52(10):3737-44. doi: 10.1128/AAC.00265-08. Epub 2008 Jul 21.

7.

Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up.

Schledermann D, Andersen BT, Bisgaard K, Dohse M, Ejersbo D, Hoelund B, Horal P, Lindh M, Ryd W.

Diagn Cytopathol. 2008 Jul;36(7):453-9. doi: 10.1002/dc.20822.

PMID:
18528890
8.

Tracing of norovirus outbreak strains in mussels collected near sewage effluents.

Nenonen NP, Hannoun C, Horal P, Hernroth B, Bergström T.

Appl Environ Microbiol. 2008 Apr;74(8):2544-9. doi: 10.1128/AEM.02477-07. Epub 2008 Feb 29.

9.

Real-time Taqman PCR targeting 14 human papilloma virus types.

Lindh M, Görander S, Andersson E, Horal P, Mattsby-Balzer I, Ryd W.

J Clin Virol. 2007 Dec;40(4):321-4. Epub 2007 Nov 5.

PMID:
17981499
10.

Outbreak of norovirus in Västra Götaland associated with recreational activities at two lakes during August 2004.

Sartorius B, Andersson Y, Velicko I, De Jong B, Löfdahl M, Hedlund KO, Allestam G, Wångsell C, Bergstedt O, Horal P, Ulleryd P, Soderstrom A.

Scand J Infect Dis. 2007;39(4):323-31.

PMID:
17454896
11.

Predictive factors and virological response to interferon treatment in children with chronic hepatitis B.

Söderström A, Lindh M, Ekholm K, Conradi N, Horal P, Krantz M, Hultgren C, Norkrans G.

Scand J Infect Dis. 2005;37(1):40-7.

PMID:
15764189
12.

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Jejcic A, Höglund S, Balzarini J, Vahlne A, Svennerholm B.

Antimicrob Agents Chemother. 2005 Jan;49(1):40-4.

13.

Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).

Balzarini J, Andersson E, Schols D, Proost P, Van Damme J, Svennerholm B, Horal P, Vahlne A.

Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59.

PMID:
15183349
14.

No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Vahlne A, Svennerholm B.

Antiviral Res. 2004 Feb;61(2):119-24.

PMID:
14670585
15.

Histologic activity of childhood chronic hepatitis B related to viremia levels, genotypes, mutations, and epidemiologic factors.

Söderström A, Norkrans G, Conradi N, Krantz M, Horal P, Lindh M.

J Pediatr Gastroenterol Nutr. 2002 Oct;35(4):487-94.

PMID:
12394372
16.

Genotype mixtures of hepatitis B virus in patients treated with interferon.

Hannoun C, Krogsgaard K, Horal P, Lindh M; Interpred trial group.

J Infect Dis. 2002 Sep 15;186(6):752-9. Epub 2002 Aug 28.

PMID:
12198608
17.

Hepatitis B virus genotypes in Mongols and Australian Aborigines.

Alestig E, Hannoun C, Horal P, Lindh M.

Arch Virol. 2001 Dec;146(12):2321-9.

PMID:
11811682
18.

Mutations in the X region and core promoter are rare and have little impact on response to interferon therapy for chronic hepatitis B.

Hannoun C, Horal P, Krogsgaard K, Lindh M; INTERPRED Study Group.

J Med Virol. 2002 Feb;66(2):171-8.

PMID:
11782925
19.
20.

Virological response to interferon therapy of chronic hepatitis B as measured by a highly sensitive assay.

Lindh M, Hannoun C, Horal P, Krogsgaard K; Interpred Study Group.

J Viral Hepat. 2001 Sep;8(5):349-57.

PMID:
11555192
21.

Phylogenetic origin of hepatitis B virus strains with precore C-1858 variant.

Alestig E, Hannoun C, Horal P, Lindh M.

J Clin Microbiol. 2001 Sep;39(9):3200-3.

22.

The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.

Su J, Naghavi MH, Jejcic A, Horal P, Furuta Y, Wu YP, Li SL, Hall WW, Goobar-Larsson L, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):8-15.

PMID:
11213934
23.

The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

Su J, Andersson E, Horal P, Naghavi MH, Palm A, Wu YP, Eriksson K, Jansson M, Wigzell H, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):1-7.

PMID:
11213928
24.

Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection.

Mahieux R, Horal P, Mauclère P, Mercereau-Puijalon O, Guillotte M, Meertens L, Murphy E, Gessain A.

J Clin Microbiol. 2000 Nov;38(11):4049-57.

26.

Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B.

Lindh M, Horal P, Dhillon AP, Norkrans G.

J Viral Hepat. 2000 Jul;7(4):258-67.

PMID:
10886534
27.

Acute hepatitis B in Western Sweden--genotypes and transmission routes.

Lindh M, Horal P, Norkrans G.

Infection. 2000 May-Jun;28(3):161-3.

PMID:
10879641
28.

Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection.

Noborg U, Gusdal A, Horal P, Lindh M.

Scand J Infect Dis. 2000;32(3):249-52.

PMID:
10879593
29.

Long-term mutation rates in the hepatitis B virus genome.

Hannoun C, Horal P, Lindh M.

J Gen Virol. 2000 Jan;81(Pt 1):75-83.

PMID:
10640544
30.

HBeAg immunostaining of liver tissue in various stages of chronic hepatitis B.

Lindh M, Savage K, Rees J, Garwood L, Horal P, Norkrans G, Dhillon AP.

Liver. 1999 Aug;19(4):294-8.

PMID:
10459627
31.

Chronic hepatitis B in children in Gothenburg, Sweden.

Söderström A, Lindh M, Eriksson K, Horal P, Krantz M, Kristiansson B, Lindberg J, Norkrans G.

Scand J Infect Dis. 1999;31(2):109-14.

PMID:
10447315
32.

Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers.

Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P.

J Infect Dis. 1999 Apr;179(4):775-82.

PMID:
10068571
33.

Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon.

Lindh M, Gonzalez JE, Norkrans G, Horal P.

J Virol Methods. 1998 Jun;72(2):163-74.

PMID:
9694324
34.
35.

Identification of exposed epitopes on the envelope glycoproteins of human T-cell lymphotropic virus type I (HTLV-I)

Grange MP, Rosenberg AR, Horal P, Desgranges C.

Int J Cancer. 1998 Mar 2;75(5):804-13.

36.

Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity.

Broliden K, Von Gegerfelt A, Persson C, Horal P, Svennerholm B, Wahren B, Björling E, Vahlne A.

AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1699-702.

PMID:
8959246
37.

Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage.

Lindh M, Horal P, Dhillon AP, Furuta Y, Norkrans G.

Hepatology. 1996 Sep;24(3):494-501.

PMID:
8781313
39.
40.

Detection of hepatitis B virus precore TAG mutant by an amplification-created restriction site method.

Lindh M, Furuta Y, Ljunggren KK, Norkrans G, Horal P.

J Infect Dis. 1995 Jan;171(1):194-7.

PMID:
7798663
41.

Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.

Furuta Y, Eriksson K, Svennerholm B, Fredman P, Horal P, Jeansson S, Vahlne A, Holmgren J, Czerkinsky C.

Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12559-63.

42.

HIV type 1 V3 sequence diversity in contact-traced Swedish couples at the time of sexual transmission.

Furuta Y, Bergström T, Norkrans G, Horal P.

AIDS Res Hum Retroviruses. 1994 Sep;10(9):1187-9. No abstract available.

PMID:
7826703
43.

Prevalence of HIV-1 infection in rural, semi-urban and urban villages in southwest Tanzania: estimates from a blood-donor study.

Söderberg S, Temihango W, Kadete C, Ekstedt B, Masawe A, Vahlne A, Horal P.

AIDS. 1994 Jul;8(7):971-6.

PMID:
7946108
44.

Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.

Desgranges C, Souche S, Vernant JC, Smadja D, Vahlne A, Horal P.

AIDS Res Hum Retroviruses. 1994 Feb;10(2):163-73.

PMID:
8198868
45.

Possible association of HTLV-I infection and dementia.

Lycke J, Svennerholm B, Svenningsson A, Horal P, Nordqvist-Brandt E, Andersen O.

Acta Neurol Scand. 1993 Sep;88(3):199-203.

PMID:
8256556
46.
47.

Amplified ELISPOT assay for the detection of HIV-specific antibody-secreting cells in subhuman primates.

Eriksson K, Nordström I, Horal P, Jeansson S, Svennerholm B, Vahlne A, Holmgren J, Czerkinsky C.

J Immunol Methods. 1992 Aug 30;153(1-2):107-13.

PMID:
1517581
48.

Use of immunoreactive synthetic HTLV-1 peptides in the search for antibody reactivity in multiple sclerosis.

Lycke J, Andersen O, Svennerholm B, Ben-Menachem E, Horal P, Vahlne A.

Acta Neurol Scand. 1992 Jan;85(1):44-54.

PMID:
1546533
49.

Inhibition of herpes simplex virus production in vitro by cyclosporin A.

Vahlne A, Larsson PA, Horal P, Ahlmén J, Svennerholm B, Gronowitz JS, Olofsson S.

Arch Virol. 1992;122(1-2):61-75.

PMID:
1309645
50.

Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.

Vahlne A, Horal P, Eriksson K, Jeansson S, Rymo L, Hedström KG, Czerkinsky C, Holmgren J, Svennerholm B.

Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10744-8.

Supplemental Content

Support Center